EP MedSystems Receives European Approval for EP-WorkMate
with RPM Catheter Navigation Technology

WEST BERLIN, N.J.--(BUSINESS WIRE)--July 27, 2004--EP MedSystems, Inc. (NASDAQ: EPMD -News), a market leader in electrophysiology (EP) products used to diagnose and treat certain types of cardiac rhythm disorders, announced today that it has received regulatory approval from the European Notified Body for its integration of Boston Scientific Corporation's RPM(TM) Real-time Position Management(TM) technology with EP MedSystems' EP-WorkMate® workstation. This approval allows the CE mark to be affixed onto the product allowing the Company to sell it within the 15 countries of the European Community. The new EP-WorkMate® with RPM(TM) is currently the only EP recording system available on the market to integrate advanced recording and stimulation, with anatomic modeling, advanced mapping and 3D navigation features, allowing electrophysiologic studies to be more efficient and user friendly.

This approval continues to open up new market opportunities and we continue to work closely with the Company's joint-development partner Boston Scientific Corporation. The EP-WorkMate® with RPM(TM) integrated EP recording and navigation system is the culmination of a joint-development project with the electrophysiology business unit of Boston Scientific Corporation (NYSE: BSX -News)

Reinhard Schmidt, President and CEO of EP MedSystems commented, "This approval is another significant milestone for the company as we continue our roll out of new products into the marketplace. In conjunction with Boston Scientific, we have seen a strong response from the marketplace in the United States, with our new EP WorkMate® with RPM(TM) offering, allowing physicians a more efficient and user friendly product." Mr. Schmidt concluded, "The RPM(TM) upgrade provides an easy, cost effective way for our installed base to participate in the market trend toward anatomical modeling, advanced mapping and 3-D navigation for complex ablation procedures. International expansion is a key driver of future growth for the EP MedSystems and this approval is yet another successful step in our growth strategy."

About EP MedSystems:
EP MedSystems develops and markets cardiac electrophysiology ("EP") products used to diagnose and treat certain cardiac rhythm disorders. The Company's EP product line includes the EP-WorkMate® Electrophysiology Workstation with RPM(TM) Real-time Position Management(TM) navigation technology, the EP-4(TM) Computerized Cardiac Stimulator, fixed and deflectable diagnostic electrophysiology catheters and related disposable supplies, the ALERT® System and ALERT family of internal cardioversion catheters, and the ViewMate® intracardiac ultrasound catheter imaging. For more information, visit our Website at www.epmedsystems.com.

Forward Looking Statements:
This Release may contain certain statements of a forward-looking nature relating to future events or the future financial performance of the Company. Forward-looking statements include information concerning our possible or assumed future results of operations and statements preceded by, followed by or including the words "believes", "expects", "anticipates", "intends", "plans", "estimates", "see opportunities" or similar expressions. Such forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such forward-looking statements are only predictions and are subject to risks and uncertainties that could cause actual results or events to differ materially and adversely from the events discussed in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, EP MedSystems' history of losses, uncertainty of market acceptance of our products and level of sales, uncertainty of future profitability and future liquidity needs, possible costs, fines or penalties that may be incurred in connection with government inquiries and investigations and risks regarding regulatory approvals and demand for new and existing products, as stated in the Company's Annual Report filed on Form 10-KSB and quarterly reports filed on Form 10-Q and 10-QSB.

EP MedSystems cautions investors and others to review the cautionary statements set forth in this press release and in EP MedSystems' reports filed with the Securities and Exchange Commission and cautions that other factors may prove to be important in affecting the EP MedSystems' business and results of operations. Readers are cautioned not to place undue reliance on this press release and other forward-looking statements, which speak only as of the date of this release. EP MedSystems undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date of this report or to reflect the occurrence of unanticipated events.

For Further Information Contact:

EP MedSystems, Inc.
Matthew C. Hill
(856)753-8533

Investor Relations Firm:
MKR Group, LLC
Charles Messman, Todd Kehrli
(818)556-3700